Multicenter randomized trial of cell therapy in cardiopathies - MiHeart Study

Página do item simplificado
dc.contributor.authorTura, Bernardo R
dc.contributor.authorMartino, Helena F
dc.contributor.authorGowdak, Luis H
dc.contributor.authorSantos, Ricardo Ribeiro dos
dc.contributor.authorDohmann, Hans F
dc.contributor.authorKrieger, José E
dc.contributor.authorFeitosa, Gilson
dc.contributor.authorVilas-Boas, Fabio
dc.contributor.authorOliveira, Sergio A
dc.contributor.authorSilva, Suzana A
dc.contributor.authorBozza, Augusto Z
dc.contributor.authorBorojevic, Radovan
dc.contributor.authorCarvalho, Antonio C Campos de
dc.date.accessioned2023-12-21T14:44:30Z
dc.date.available2023-12-21T14:44:30Z
dc.date.issued2007
dc.description.abstractBackground: Cardiovascular diseases are the major cause of death in the world. Current treatments have not been able to reverse this scenario, creating the need for the development of new therapies. Cell therapies have emerged as an alternative for cardiac diseases of distinct causes in experimental animal studies and more recently in clinical trials. Method/design: We have designed clinical trials to test for the efficacy of autologous bone marrow derived mononuclear cell therapies in four different cardiopathies: acute and chronic ischemic heart disease, and Chagasic and dilated cardiomyopathy. All trials are multicenter, randomized, double-blind and placebo controlled. In each trial 300 patients will be enrolled and receive optimized therapy for their specific condition. Additionally, half of the patients will receive the autologous bone marrow cells while the other half will receive placebo (saline with 5% autologous serum). For each trial there are specific inclusion and exclusion criteria and the method for cell delivery is intramyocardial for the chronic ischemic heart disease and intracoronary for all others. Primary endpoint for all studies will be the difference in ejection fraction (determined by Simpson's rule) six and twelve months after intervention in relation to the basal ejection fraction. The main hypothesis of this study is that the patients who receive the autologous bone-marrow stem cell implant will have after a 6 month follow-up a mean increase of 5% in absolute left ventricular ejection fraction in comparison with the control group. Discussion: Many phase I clinical trials using cell therapy for cardiac diseases have already been performed. The few randomized studies have yielded conflicting results, rendering necessary larger well controlled trials to test for efficacy of cell therapies in cardiopathies. The trials registration numbers at the NIH registry are the following: Chagasic cardiomyopathy (NCT00349271), dilated cardiomyopathy (NCT00333827), acute myocardial infarction (NCT00350766) and Chronic Ischemic Heart Disease (NCT00362388).
dc.identifier.citationTura BR, Martino HF, Gowdak LH, dos Santos RR, Dohmann HF, Krieger JE, Feitosa G, Vilas-Boas F, Oliveira SA, Silva SA, Bozza AZ, Borojevic R, de Carvalho AC. Multicenter randomized trial of cell therapy in cardiopathies - MiHeart Study. Trials. 2007 Jan 18;8:2. doi: 10.1186/1745-6215-8-2.
dc.identifier.otherDOI: 10.1186/1745-6215-8-2
dc.identifier.urihttps://dspace.inc.saude.gov.br/handle/123456789/385
dc.language.isoen
dc.publisherTrials
dc.titleMulticenter randomized trial of cell therapy in cardiopathies - MiHeart Study
dc.typeArticle
Arquivos
Original bundle
Agora exibindo 1 - 1 de 1
thumbnail.default.alt
Nome:
Tura BR et al_Trials.pdf
Tamanho:
162.82 KB
Formato:
Adobe Portable Document Format
Descrição:
Baixar
License bundle
Agora exibindo 1 - 1 de 1
thumbnail.default.placeholder
Nome:
license.txt
Tamanho:
1.71 KB
Formato:
Item-specific license agreed to upon submission
Descrição:
Baixar
Coleções
Produção Docente
Produção Bibliográfica